|
Site-Specific Antibody Customization & Precise Conjugation
hits:66 Date:11/13/26
This document focuses on site‑specific antibody conjugation technology — a core innovation for next‑generation antibody‑drug conjugates (ADCs) and high‑precision antibody research tools.
1. Why Site‑Specific Conjugation Is Essential
Traditional random conjugation causes high heterogeneity, unstable quality, and impaired antigen binding.
Site‑specific modification produces homogeneous, stable, and highly active conjugates.
Improves safety, pharmacokinetics, tumor targeting, and therapeutic window.
2. Core Technologies for Site‑Specific Conjugation
Chemoenzymatic Methods (for native antibodies)
Transglutaminase method: Targets Gln295 in Fc; forms stable amide bonds.
Glycan remodeling: Modifies the conserved N‑glycan at Asn297; highly uniform.
Chemical Methods
Controlled disulfide bond rebridging: Selectively re-links interchain disulfides.
N‑terminal α‑amine modification: Specific labeling without affecting lysines.
3. Clinical & Preclinical Value
Site‑specific ADCs now account for 100% of new clinical ADC candidates (since 2020).
Improved stability, reduced off‑target toxicity, and enhanced tumor accumulation.
Widely applied in solid tumor therapy.
4. Future Trends
Advanced linkers: cleavable / pH‑sensitive / redox‑sensitive / branched.
Click chemistry for higher efficiency.
Expansion to nanobodies, bispecific antibodies, and novel formats.
5. ANT BIO PTE. LTD. Site‑Specific Antibody Customization Service
The company provides high‑precision site‑specific antibody development for modified or mutated protein targets.
Core Strengths
Custom antigen design for methylation, acetylation, ubiquitination, point mutations, etc.
Two‑step purification: negative adsorption + positive enrichment for ultrahigh specificity.
Strict validation (Dot Blot, ELISA, WB) to ensure no cross‑reaction with wild type.
Flexible polyclonal / monoclonal antibody production.
Applications
Epigenetics, signal transduction, disease biomarkers, diagnostic reagents, and targeted drug development.
Conclusion
Site‑specific antibody conjugation solves the limitations of traditional random modification, enabling highly homogeneous, stable, and potent antibody conjugates. Supported by advanced chemoenzymatic and chemical strategies, it has become the mainstream direction for ADCs and precision antibody tools.
|
中文
